{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT07409272","nct_id":"NCT07409272","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct07409272. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive setidegrasib once weekly plus mFOLFIRINOX (oxaliplatin, leucovorin \\[folinic acid or levofolinate\\], irinotecan and 5-FU) or NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin \\[or levofolinate\\] and 5 FU) chemotherapy on a 28-day cycle.","label":"Setidegrasib plus chemotherapy","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo once weekly plus mFOLFIRINOX (oxaliplatin, leucovorin \\[folinic acid or levofolinate\\], irinotecan and 5-FU) or NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin \\[or levofolinate\\] and 5 FU) chemotherapy on a 28-day cycle.","label":"Placebo plus chemotherapy","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-08-31","type":"ESTIMATED"},"conditions":["Pancreatic Cancer","Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma"],"enrollment":{"count":614,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Setidegrasib","otherNames":["ASP3082"],"type":"DRUG"},{"name":"Oxaliplatin","otherNames":[],"type":"DRUG"},{"name":"Leucovorin","otherNames":["folinic acid","levofolinate"],"type":"DRUG"},{"name":"Irinotecan","otherNames":[],"type":"DRUG"},{"name":"fluorouracil","otherNames":["5-FU"],"type":"DRUG"},{"name":"liposomal irinotecan","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-22","lead_sponsor":"Astellas Pharma Global Development, Inc.","official_title":"A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-08-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to 3.5 years"}],"references":[],"start_date":{"date":"2026-02-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT07409272"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct07409272"}